<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858545</url>
  </required_header>
  <id_info>
    <org_study_id>ACL2011-002-I</org_study_id>
    <nct_id>NCT01858545</nct_id>
  </id_info>
  <brief_title>A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers</brief_title>
  <official_title>An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers Resistant to Standard of Care: A Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACell Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACell Inc.</source>
  <oversight_info>
    <authority>United States: Western IRB</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effectiveness of MatriStem devices
      compared to cellular dermal replacement tissue, for the treatment of non-healing diabetic
      foot ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to their characteristically poor healing capacity, diabetic foot ulcers (DFUs) are
      challenging for clinicians to treat.  This prospective, multi-center clinical study will
      examine outcomes following treatment of DFUs, with one of two FDA cleared tissue-engineered
      devices, MatriStemÂ® or cellular dermal replacement tissue, on DFUs that have demonstrated an
      inadequate response to initial standard of care therapy.  The incidence of ulcer closure,
      rate of wound closure, and quality of life will be evaluated over a eight week period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The incidence of complete wound closure</measure>
    <time_frame>8 Week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measures</measure>
    <time_frame>12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Diabetes, Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MatriStem MicroMatrix and MatriStem Wound Matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cellular Dermal Replacement Tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MatriStem</intervention_name>
    <description>MatriStem MicroMatrix and MatriStem Wound Matrix</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellular Dermal Replacement Tissue</intervention_name>
    <description>Cellular Dermal Replacement Tissue</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a current diagnosis of type I or type II diabetes.

          -  Subject has chronic ulcer

        Exclusion Criteria:

          -  Subject has a known sensitivity to bovine- or porcine-derived products.

          -  Subject's ulcer is due to a non-diabetic etiology
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Kofron, Ph.D.</last_name>
    <phone>4109538502</phone>
    <email>michellekofron@acell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Mattingly</last_name>
    <phone>410-953-9539</phone>
    <email>cindymattingly@acell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Associated Foot &amp; Ankle Specialists, PC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Ramos</last_name>
      <phone>602-274-4100</phone>
      <email>norma.ramos@qwestoffice.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tucson Orthopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Placencia</last_name>
      <phone>520-784-6430</phone>
      <email>cplacencia@tucsonortho.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research Inc.</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayana Sarkisova, CCRC</last_name>
      <phone>415-710-3061</phone>
      <email>gayana@ccr-trials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Duncan, RN</last_name>
      <phone>202-444-7288</phone>
      <email>joanna.c.duncan@gunet.georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zinnia Rocha, CRC</last_name>
      <phone>202-444-0793</phone>
      <email>Zinnia.M.Rocha@gunet.georgetown.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NewPhase Clinical Trials, Corp.</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Gonzalez, CCRC, RCVT</last_name>
      <phone>305-858-4300</phone>
      <email>lourdes.gonzalez@newphaseclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Eggers, CMA</last_name>
      <phone>208-377-8653</phone>
      <phone_ext>115</phone_ext>
      <email>keggers@acr-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Allie Lopez</last_name>
      <phone>208-377-8653</phone>
      <phone_ext>105</phone_ext>
      <email>alopez@acr-research.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>May 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
